Lumosa Therapeutics received its second national award in two days. Just one day after receiving the 2015 National Innovation Award (12/25), Lumosa's LT1001 (Naldebain™, SDE) was recognized jointly-Drug Research and Development Science and Technology Bronze Award in the pharmaceutical category. The award was held to encourage innovative research and development in pharmaceutical industry, enhance the quality of clinical trials and manufacturing standards, and strengthen Taiwan’s competitiveness among global pharmaceutical technology industry. CEO Dr. Wendy Huang and Head of Pharmaceutical Development, Dr. David Chou, accepted the trophy and certificate from Ms. Yu-mei Chiang, Director-General of TFDA and Mr. Cheng-hua Lu, Deputy-Director, Industrial Development Bureau of the MOEA, on behalf of Lumosa Therapeutics. LT1001 features an extended release formulation which provides up to 7-day analgesic effect, low side effects, and low risk of addiction. The product is designed to effectively elevate patient quality of life and reduce burden of healthcare professionals. This second award reconfirmed the successful development program and the accomplishment of the Lumosa R&D team. Lumosa is looking forward to achieve the next milestones when LT1001 is approved for marketing and launched in the future.